Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Impact · against what's priced in

The announcement of a deadline for lead plaintiff motions in a securities fraud lawsuit is a procedural update with negligible impact on Aardvark Therapeutics' valuation. The underlying catalysts—the FDA clinical hold and the voluntary trial pause—are already reflected in the stock price.

AARD−0.05

No priced-in read yet